Table 2.
Univariate and multivariate Cox regression analysis of Overall survival (ICC Training Cohort)
| Characteristics | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR(95%CI) | P-value | HR(95%CI) | P-value | |
| Age | < 0.001 | < 0.001 | ||
| < 68 | Reference | Reference | ||
| 68–78 | 2.025 (1.071–3.827) | 0.030 | 2.576 (1.262–5.258) | 0.009 |
| 79+ | 8.326 (4.848–14.299) | < 0.001 | 14.362 (7.309–28.222) | < 0.001 |
| Race | 0.228 | |||
| White | Reference | |||
| Black | 1.508 (0.746–3.051) | 0.253 | ||
| Other | 0.546 (0.198–1.506) | 0.242 | ||
| Sex | 0.355 | |||
| Female | Reference | |||
| Male | 1.944 (0.476–7.945) | 0.355 | ||
| Marital | 0.003 | < 0.001 | ||
| Married | Reference | Reference | ||
| Single | 2.343 (1.251–4.389) | 0.008 | 4.087 (2.019–8.275) | < 0.001 |
| Divorced | 2.371 (1.382–4.068) | 0.002 | 1.66 (0.888–3.105) | 0.113 |
| Site | 0.038 | 0.022 | ||
| Other | Reference | Reference | ||
| 502 | 0.392 (0.165–0.929) | 0.033 | 0.485 (0.201–1.171) | 0.108 |
| 503 | 0.206 (0.028–1.504) | 0.119 | 0.217 (0.025–1.87) | 0.164 |
| 504 | 0.525 (0.307–0.897) | 0.018 | 0.45 (0.25–0.813) | 0.008 |
| 505 | 0.55 (0.196–1.545) | 0.257 | 0.309 (0.102–0.941) | 0.039 |
| Laterality | 0.317 | |||
| Left | Reference | |||
| Right | 0.782 (0.484–1.266) | 0.317 | ||
| Grade | ||||
| I + II | Reference | |||
| II + IV | 1.057 (0.425–2.628) | 0.904 | ||
| AJCC stage | < 0.001 | |||
| I | Reference | |||
| II | 1.413 (0.829–2.409) | 0.204 | ||
| III | 1.901 (0.678–5.335) | 0.222 | ||
| IV | 32.616 (13.295–80.013) | < 0.001 | ||
| T stage | < 0.001 | < 0.001 | ||
| T1 | Reference | Reference | ||
| T2 | 1.777 (1.026–3.079) | 0.040 | 1.656 (0.887–3.094) | 0.113 |
| T3 | 1.711 (0.531–5.516) | 0.368 | 2.175 (0.651–7.266) | 0.207 |
| T4 | 12.661 (4.522–35.453) | 0.000 | 40.392 (9.908–164.669) | < 0.001 |
| N stage | 0.070 | |||
| N0 | Reference | |||
| N1 | 1.034 (0.527–2.029) | 0.922 | ||
| N2 | 0.768 (0.106–5.55) | 0.793 | ||
| N3 | 4.78 (1.49–15.333) | 0.009 | ||
| M stage | < 0.001 | < 0.001 | ||
| M0 | Reference | Reference | ||
| M1 | 28.362 (11.839–67.949) | < 0.001 | 52.29 (13.76–198.705) | < 0.001 |
| ER status | 0.749 | |||
| Negative | Reference | |||
| Positive | 1.208 (0.379–3.847) | 0.749 | ||
| PR status | 0.001 | 0.001 | ||
| Negative | Reference | Reference | ||
| Positive | 0.408 (0.236–0.706) | 0.001 | 0.363 (0.199–0.662) | 0.001 |
| HER-2 status | 0.199 | |||
| Negative | Reference | |||
| Positive | 2.273 (0.677–7.629) | 0.184 | ||
| Unknown | 0.781 (0.436–1.398) | 0.405 | ||
| Surgery | < 0.001 | 0.019 | ||
| No | Reference | Reference | ||
| Yes | 0.127 (0.058–0.278) | < 0.001 | 0.27 (0.09–0.809) | 0.019 |
| Radiaotherapy | < 0.001 | |||
| No | Reference | |||
| Yes | 0.343 (0.205–0.574) | < 0.001 | ||
| Chemotherapy | 0.009 | |||
| No | Reference | |||
| Yes | 0.353 (0.161–0.771) | 0.009 | ||
Abbreviations: ICC Invasive cribriform carcinoma, IDC Infiltrating ductal carcinoma, 502 Upper-inner quadrant of breast, 503 Lower-inner quadrant of breast, 504 Upper-outer quadrant of breast, 505 Lower-outer quadrant of breast, ER Estrogen receptor, PR Progesterone receptor, HER-2 Human epidermal growth factor receptor 2